China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g – an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL

SUZHOU and SHANGHAI, China, Jan. 13, 2021 /PRNewswire/ --  Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to d...

Full "IntellAsia: Resources" article